Document is current
Any future updates will be listed below
-
Authors
Solimando, Antonio Giovanni https://orcid.org/0000-0002-2293-9698
Di Palma, Francesco https://orcid.org/0009-0008-3164-6484
Desantis, Vanessa https://orcid.org/0000-0003-1942-2601
Vacca, Angelo https://orcid.org/0000-0002-4567-8216
Svelto, Maria https://orcid.org/0000-0002-5584-9541
Pisani, Francesco https://orcid.org/0000-0001-8511-117X
-
Funding
Funding for this research was provided by:
Ministero dell'Istruzione, dell'Università e della Ricerca (CN00000041, CN00000041, 2022ZKKWLW)
Ministero della Salute (T4-AN-01, T4-AN-01)
- License Information
-
More Information
Article History
Received: 4 November 2024
Revised: 13 December 2024
Accepted: 2 January 2025
First Online: 9 January 2025
Competing interests
: AGS has received speaker honoraria from Sanofi, Amgen, and AstraZeneca. He has also participated in advisory boards for Pfizer and Menarini and received travel support for educational purposes from Janssen-Cilag. AV received speaker honoraria from Pfizer, Sanofi, Bristol Myers Squibb, Takeda, Janssen-Cilag, AstraZeneca, Menarini, and Amgen. Their potential conflicts of interest do not imply bias or influence on the authors’ opinions or actions. The authors recognize the importance of transparency in the scientific field and are committed to upholding their integrity and maintaining trust in them within the scientific community.
: This study was conducted following the Declaration of Helsinki, the Council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines, applicable International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH-GCP) Good Clinical Practice guidelines, and applicable local laws and regulations. The study protocol was reviewed and approved by Institutional Review Boards and an Independent Ethics Committee (Resolution No. 1300, dated 12/21/2023). All subjects involved provided signed informed consent.
